Emervel for the Correction of Lower Face Wrinkles & Folds
Launched by GALDERMA R&D · Mar 18, 2016
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Key Inclusion Criteria:
- • 1. Seeking correction of bilateral NLFs: severe (i.e., bilateral WSRS = 3-4) or moderate (i.e., bilateral WSRS = 2-3) AND bilateral MLs: severe (i.e., WAS = 3-4) or moderate (i.e., WAS = 2-3).
- • 2. Subjects of childbearing potential who agree to use medically accepted methods of contraception during the study and for 30 days following study completion.
- • 3. Intent to undergo optimal correction of bilateral NLFs and MLs. Optimal correction is defined as the best possible aesthetic outcome as agreed to by the treating investigator and subject.
- Key Exclusion Criteria:
- • 1. Subject who presents with a severity of wrinkles or folds that require other treatments, e.g. laser treatment, chemical peeling, to achieve optimal correction.
- • 2. Previous facial surgery, including aesthetic facial surgical therapy, liposuction or tattoo, in the treatment area.
- • 3. Previous tissue augmenting therapy or contouring with permanent or non-permanent filler or fat-injection in the facial area.
- • 4. Previous tissue revitalization treatment with neurotoxin in the facial area within 6 months before treatment.
- • 5. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel.
- • 6. Known/previous allergy or hypersensitivity to local anaesthetics, e.g. lidocaine or other amide-type anaesthetics.
- • 7. Known/previous allergy or hypersensitivity to gram-positive bacterial proteins.
- • 8. Any medical condition that, in the opinion of the treating investigator, would make the subject unsuitable for inclusion (e.g. a chronic, relapsing or hereditary disease that may interfere with the outcome of the study).
- • 9. Other condition preventing the subject from entering the study in the treating investigator's opinion, e.g. subjects not likely to avoid other facial cosmetic treatments, subjects anticipated to be unreliable, unavailable or incapable of understanding the study assessments or having unrealistic expectations of the treatment result.
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jay Mashburn
Study Director
Galderma Laboratories
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials